Wird geladen...
How will B-cell-receptor–targeted therapies change future CLL therapy?
For many years there has been considerable disassociation between the understood biology of chronic lymphocytic leukemia (CLL) and the therapeutics used to treat this disease. With the introduction of the first targeted CD20 antibody rituximab and its addition to chemotherapy came the first observat...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3945859/ https://ncbi.nlm.nih.gov/pubmed/24394667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-453092 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|